^
Association details:
| Biomarker: | HLA-A*02 + MAGEA4 expression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Tecelra (afamitresgene autoleucel) (TCR modulator, MAGE-A4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.
Published date:
05/26/2022
Excerpt:
Eligible pts (16–75 years) were HLA-A*02+ with MAGE-A4+ tumors....Response rate was higher in the 59 pts with SyS: with ≤2 vs ≥3 prior lines of therapy (55.2% vs 26.7%)….In responders vs non-responders with SyS, respectively, median PFS was 58.3 vs 11. 0 weeks (log-rank p-value <0.0001); the probability of being progression-free at 24 weeks was 0.8 vs 0.2....We show that baseline tumor burden, prior systemic treatment history, and MAGE-A4 tumor expression levels are potential factors associated with response to afami-cel...
DOI:
10.1200/JCO.2022.40.16_suppl.11562
Trial ID:
